Therapeutic Advances in Hematology

Papers
(The TQCC of Therapeutic Advances in Hematology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias37
Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib36
Bortezomib in autoimmune hemolytic anemia and beyond27
Venetoclax-containing regimens in acute myeloid leukemia27
Current evidence and the emerging role of eltrombopag in severe aplastic anemia27
B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies26
Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria22
Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review20
Expression of γ-globin genes in β-thalassemia patients treated with sirolimus: results from a pilot clinical trial (Sirthalaclin)19
Primary central nervous system lymphoma in the United States, 1975–201719
Clinical features of DDX41 mutation-related diseases: a systematic review with individual patient data19
The potential of pirtobrutinib in multiple B-cell malignancies19
Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor18
International consensus recommendations on the management of people with haemophilia B18
Ferumoxytol for the treatment of iron deficiency and iron-deficiency anemia of pregnancy18
Current and emerging treatment options in primary mediastinal B-cell lymphoma16
Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia16
MYD88L265P and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy15
The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria15
Current state of CAR-T therapy for T-cell malignancies15
Current options and future perspectives in the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma15
Advances in therapeutic options for newly diagnosed, high-risk AML patients14
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data14
Rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in diffuse large B-cell lymphoma13
Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implications13
The role of tazemetostat in relapsed/refractory follicular lymphoma13
Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective13
The evolving role of Bruton’s tyrosine kinase inhibitors in chronic lymphocytic leukemia13
The role of carfilzomib in relapsed/refractory multiple myeloma13
Current and novel BTK inhibitors in Waldenström’s macroglobulinemia13
Antibiotic use and ileocolonic immune cells in patients receiving fecal microbiota transplantation for refractory intestinal GvHD: a prospective cohort study13
Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL)12
Efficacy and safety of cyclosporine A treatment in autoimmune cytopenias: the experience of two Italian reference centers12
A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy12
Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma12
Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations10
Cardiovascular-specific mortality among multiple myeloma patients: a population-based study10
Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma10
Mantle cell lymphoma management trends and novel agents: where are we going?10
Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation10
The role of acalabrutinib in adults with chronic lymphocytic leukemia9
Acute myeloid leukemia with CPSF6–RARG fusion resembling acute promyelocytic leukemia with extramedullary infiltration9
Emicizumab in acquired haemophilia A: about two clinical cases and literature review9
The role of idecabtagene vicleucel in patients with heavily pretreated refractory multiple myeloma9
CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma9
Advancing the standard: venetoclax combined with intensive induction and consolidation therapy for acute myeloid leukemia9
Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study9
A retrospective comparison of salvage intensive chemotherapy versus venetoclax-combined regimen in patients with relapsed/refractory acute myeloid leukemia (AML)8
Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft-versus-host disease after haploidentical allogeneic hematopoietic stem cell transplantation8
Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE)8
Outpatient allogeneic hematopoietic stem-cell transplantation: a review8
Update on the role of copanlisib in hematologic malignancies8
Safety and efficacy of a single total dose infusion (1020 mg) of ferumoxytol8
How to translate and implement the current science of gene therapy into haemophilia care?8
The use of tafasitamab in diffuse large B-cell lymphoma8
Treosulfan-based conditioning for inborn errors of immunity7
Treatment de-escalation in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia: the emerging role of chemotherapy-free regimens7
Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide7
Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study7
Current treatment options for aggressive non-Hodgkin lymphoma in elderly and frail patients: practical considerations for the hematologist7
Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 109/L to <100 × 109/L) at baseline: the final analysis of EXPAND7
Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report7
Association between preconditioning absolute lymphocyte count and transplant outcomes in patients undergoing matched unrelated donor allogeneic hematopoietic stem cell transplantation with reduced-int7
Interferon-α may help prevent molecular relapse of chronic myeloid leukemia after the discontinuation of tyrosine kinase inhibitors7
Prophylactic management of patients with von Willebrand disease7
The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma7
0.022664070129395